UBS analyst Jay Sole raised the firm’s price target on Bath & Body Works to $52 from $46 and keeps a Neutral rating on the shares. Bath & Body’s “underwhelming” FY24 sales growth guidance suggests the company’s sales growth rate is taking longer to normalize post-Covid than the firm expected, the analyst tells investors in a research note. The guidance implies its sales growth rate will inflect to positive in 2H, which adds another element of risk, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BBWI:
- Bath & Body Works price target raised to $50 from $48 at BMO Capital
- Bath & Body Works price target raised to $53 from $50 at Telsey Advisory
- Bath & Body Works price target raised to $45 from $30 at Evercore ISI
- Bath & Body Works price target raised to $42 from $40 at Wells Fargo
- Bath & Body Works price target raised to $55 from $35 at TD Cowen
